News | March 05, 2024
Biocon Biologics secures Canada market entry date for YESAFILI
This agreement paves the way for the introduction of YESAFILI into the Canadian market
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Collaborative Research in AYUSH is extremely important as it bridges the gap between traditional knowledge and modern scientific research
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
Patients visiting OPD sections of hospitals use their Ayushman Bharat Health Account (ABHA) to get instant tokens to save time spent in registration queues
Subscribe To Our Newsletter & Stay Updated
